drugset / Trial / NCT05654038
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
Phase 1/2
Unknown
30 enrolled
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NaSingle-groupOpen-labelTreatment
Summary
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-CD19 universal CAR-NK(UCAR-NK) cells therapy combined with HSCT for B cell hematologic malignancies.
Timeline
- Start
- 2022-12-08
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 2e+07 cells/kg | Intravenous |